The treatment of acute diarrhea in the third millennium: a pediatrician's perspective.
Diarrheal diseases continue to be a major cause of morbidity and mortality worldwide. Although new, potentially useful drugs such as acetorphan are appearing at the horizon, the cornerstone of treatment remains a proper oral rehydration (ORT). Yet, the rates at which ORT is used are still disappointingly low. Despite dramatic progresses in the understanding of the pathophysiology of diarrhea, the list of available drugs is indeed short. Recently however, several new options have appeared that may bear a great potential in the near future. The first is a potential improvement of ORS. It was recently shown that the addition of a resistant starch to oral rehydration solution reduces fecal fluid loss and shortens the duration of diarrhea in patients with cholera. Starches that are resistant to hydrolysis by amylase in fact generate in the colon short-chain fatty acids, which are known to enhance sodium absorption. The second development in treating diarrheal disease is acetorphan (racecadotril). This enkephalinase inhibitor has in fact been shown to be effective in reducing by almost half the stool output of 135 young children with acute diarrhea. Finally, probiotics. In the last few years, they have attracted a great deal of renewed interest, particularly focusing on their effects in treating and preventing diarrheal diseases. Lactobacillus GG proved effective in several clinical trials, mostly randomized and placebo-controlled, in the prevention and/or treatment of acute diarrheal disease in children. We have recently shown (6) the safety and efficacy in its administration in the ORS, especially in Rotavirus-induced diarrheas, in a large multicenter, randomized, double blind and placebo-controlled study conducted on behalf of the ESPGHAN Working Group on Acute Diarrhea.
Guandalini
Stefano
S
Department of Pediatrics, University of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637, USA. sguandal@peds.bsd.uchicago.edu
D000208:Acute Disease; D000930:Antidiarrheals / Q000627:therapeutic use; D003967:Diarrhea / Q000628:therapy*; D005440:Fluid Therapy; D006801:Humans; D019936:Probiotics / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D015244:Thiorphan / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000930:Antidiarrheals; D011480:Protease Inhibitors; C049331:racecadotril; D015244:Thiorphan